News Highlights of the Day

2019 ASCO Annual Meeting

The 2019 ASCO Annual Meeting was held May 31-June 4, 2019, and news highlights are below. The next ASCO Annual Meeting will be May 29 to June 2, 2020. Cancer.Net posts scientific news here as soon as it becomes publicly available. Or, to receive ASCO Annual Meeting breaking news via email, sign up now to receive special editions of the Inside Cancer.Net newsletter. You can also follow Cancer.Net on Facebook or Twitter, where real-time updates will also be posted.


June 3, 2019

Thank you for using Cancer.Net as your source for breaking news and research highlights from the 2019 ASCO Annual Meeting. If you missed any of the previous days’ research or want to refer back to any of these highlights, you can find everything on the Cancer.Net Blog, which delivers cancer research news, expert perspectives, podcasts, and patient stories year-round.

Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.

Learn more about the following studies on the Cancer.Net Blog:

  • For colorectal cancer, laparoscopic surgery is as effective as open surgery in treating liver metastases

    A phase III clinical trial from Norway called OSLO-COMET found that laparoscopic surgery was as effective as open surgery to remove colorectal cancer that had spread to the liver, while causing less side effects for patients.

  • Expanding eligibility criteria would double the number of people with advanced lung cancer who could join clinical trials

    An analysis of 10,500 health records for people with advanced non-small cell lung cancer (NSCLC) from the CancerLinQ database found that broadening the eligibility criteria for clinical trials would allow almost all of these patients to enroll in clinical trials, nearly doubling the percentage from about 52% to more than 98%.

  • Advanced bladder cancer and other urothelial cancers respond to enfortumab vedotin in nearly half of patients

    A phase II clinical trial has shown that the targeted therapy enfortumab vedotin produced responses in 44% of cases of locally advanced or metastatic urothelial cancers, 90% of which are bladder cancer. Urothelial cancers also affect the upper urinary tract, including the urethra, ureters, and renal pelvis, as well as other organs next to the bladder.

Additional News From ASCO

Caring for Every Patient, Learning From Every Patient

“Caring for every patient, learning from every patient.” For ASCO President Dr. Monica Bertagnolli, this is more than just a presidential theme. To put action to words, she went out to local communities in 2018 and early 2019 to speak with patients, caregivers, and oncology professionals. In this article and video shared during the ASCO Annual Meeting Opening Session, Dr. Bertagnolli shares stories and lessons learned from these communities and takeaways for the oncology community.

Follow #ASCO19 for Up-To-Date Information

Whether you are in Chicago at the ASCO Annual Meeting or following the news from home, find up-to-date information by following @CancerDotNet on Twitter and liking Cancer.Net on Facebook. The meeting’s hashtag is #ASCO19.

For questions or to receive more information about Cancer.Net, send an email to contactus@cancer.net.


June  2, 2019

Scientific research news continues to emerge from the 2019 ASCO Annual Meeting in Chicago. Today is the plenary session, which highlights research that has the greatest potential impact on care for people with cancer.

Research highlights released today include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect how long people with multiple myeloma live, and how the Affordable Care Act resulted in earlier treatment and improved equality in care.

Learn more about the following studies on the Cancer.Net Blog:

  • Enzalutamide lengthens lives of men with metastatic prostate cancer

    A phase III clinical trial called ENZAMET found that adding the nonsteroidal anti-androgen drug enzalutamide (Xtandi) to standard hormonal therapy, also called androgen-deprivation therapy, for metastatic hormone-sensitive prostate cancer may help men live longer.

  • Maintenance therapy with olaparib slows the growth of metastatic pancreatic cancer with BRCA mutations

    A phase III clinical trial called POLO showed that using olaparib (Lynparza) after initial chemotherapy kept metastatic pancreatic cancer from worsening for a longer time if the cancer was linked with a BRCA gene mutation.

  • Income, health insurance, and place of treatment affect how long people with multiple myeloma live

    A recent study analyzing information from the National Cancer Database found that certain socioeconomic factors, especially living in an area with higher incomes, having private health insurance, and receiving treatment at an academic institute, are linked with how long people with multiple myeloma live after diagnosis.

  • Two studies show Affordable Care Act has had a positive impact on cancer care

    The Affordable Care Act (ACA) is a U.S. health care law that was passed in 2010 and has since expanded access to insurance and care for many people. Two new and separate studies suggest that the ACA helps people receive treatment earlier and improves equality in care. An analysis of information from the National Cancer Database found that more women with ovarian cancer were more likely to be diagnosed earlier and start treatment sooner after the ACA went into effect. In a different study, information from 30,386 electronic health records of people with cancer throughout the United States showed that black people were more likely to receive treatment within 30 days of a cancer diagnosis in states that increased Medicaid access due to the ACA.

Additional News From ASCO

Cancer.Net Mobile Version 5.0 Now Available

The award-winning mobile app from Cancer.Net offers intuitive, on-the-go tools to help you plan and manage your care—from diagnosis through treatment and beyond—and includes the latest oncologist-approved cancer information.

The newest version of Cancer.Net Mobile offers several new features, including the ability to track upcoming and past appointments, store full contact information for providers, and a medication log that allow users to set custom reminders with push notifications and track when medications are taken.

Download now for free on the App Store or Google Play.

Follow #ASCO19 for Up-To-Date Information

Whether you are in Chicago at the ASCO Annual Meeting or following the news from home, find up-to-date information by following @CancerDotNet on Twitter and liking Cancer.Net on Facebook. The meeting’s hashtag is #ASCO19.

For questions or to receive more information about Cancer.Net, send an email to contactus@cancer.net.


June 1, 2019

The 2019 ASCO Annual Meeting is here! Over the next few days, more than 32,000 oncology professionals from around the world will be in Chicago to present and discuss the latest research in cancer treatment and patient care. As always, Cancer.Net will keep you updated on the latest news with this special series of Inside Cancer.Net newsletters and with daily posts on the Cancer.Net Blog, discussing what this news means for patients, caregivers, and families.

The theme of the 2019 ASCO Annual Meeting is Caring for Every Patient, Learning from Every Patient. For the past year, ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, has visited local groups across the United States to learn what patients and doctors truly experience when receiving and providing cancer care. As she writes in this year’s Clinical Cancer Advances report, “Cancer treatment advances are only as good as patients’ ability to access them.” This year’s ASCO Annual Meeting strikes the balance in Dr. Bertagnolli’s theme, bringing late-breaking research news to the public and exploring the ways that access to cancer care can be improved for patients. 

Watch a patient education video with Dr. Bertagnolli explaining how the ASCO Annual Meeting changes patients’ lives.

The Latest Research News

A series of research studies were announced at today’s meeting, including treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.

Learn more about the following studies on the Cancer.Net Blog:

  • Two studies find immunotherapy may work better as first treatment for some people with advanced non-small cell lung cancer and gastrointestinal cancers

    Pembrolizumab (Keytruda) is an immunotherapy that has been approved by the U.S. Food and Drug Administration (FDA) for several advanced and metastatic cancers. The medicine works by blocking a protein on the surface of cancer cells called PD-L1, allowing the body’s immune cells to destroy the cancer. Two recent studies suggest that some cancers with a high level of PD-L1 can be treated with pembrolizumab, including non-small cell lung cancer, stomach cancer, and gastroesophageal junction cancer, helping some people to live longer, with the possibility of less side effects.

  • Adding ribociclib to hormonal therapy lengthens lives of premenopausal women with advanced breast cancer

    A phase III clinical trial called MONALEESA-7 found that adding the targeted therapy ribociclib (Kisqali) to hormonal therapy helped lengthen the lives of women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who were diagnosed before menopause.

Additional News From ASCO

Advocates: Visit the Patient Advocate Lounge!

The Patient Advocate Lounge (McCormick Place Convention Center, Room S402, South Building) is a space set aside for advocates attending the ASCO Annual Meeting to gather in a relaxed environment. Take a coffee break, network with others, and attend special sessions designed just for advocates. Find the full lounge hours and learn more about programs for patient advocates at the ASCO Annual Meeting.

Looking for Trusted Patient Information Resources?

Check out ASCO Answers patient education materials in the ASCO Store. ASCO Answers includes award-winning guides, fact sheets, and booklets, covering a broad range of important and popular topics in cancer care. Bulk quantities of these high-quality print materials are available at the ASCO Store. ASCO members save 20% on all patient education materials, and shipping is free within the United States.

Visit Cancer.Net to download free PDF versions of our materials. To request free promotional materials for your practice, please email contactus@cancer.net.

Follow #ASCO19 for Up-To-Date Information

Whether you are in Chicago at the ASCO Annual Meeting or following the news from home, find up-to-date information by following @CancerDotNet on Twitter and liking Cancer.Net on Facebook. The meeting’s hashtag is #ASCO19.

For questions or to receive more information about Cancer.Net, send an email to contactus@cancer.net.


May 15, 2019

In just a few weeks, from May 31-June 4, more than 32,000 oncology professionals from around the world will gather in Chicago, IL, to attend the 2019 ASCO Annual Meeting. There, they will present and discuss the latest research in cancer treatment and patient care. As always, Cancer.Net will share the highlighted scientific research with easy-to-read summaries for people with cancer and their family members, friends, and caregivers. This evening, several studies were released ahead of the meeting:

  • Low-fat diet reduces the risk of death from breast cancer in postmenopausal women

  • Low-dose chemotherapy regimen effective in older and frail patients with esophageal cancer

  • Genetic alterations are more common in childhood cancers than predicted

  • Entrectinib produces responses in children and adolescents with central nervous system and other tumors that have specific gene fusions in early study

  • Lenalidomide lowers risk of developing multiple myeloma in those at increased risk

Read more about this research on the Cancer.Net Blog.